STABILITY OF CAFFEINE ORAL FORMULATIONS FOR NEONATAL USE

被引:9
作者
BARNES, AR
HEBRON, BS
SMITH, J
机构
[1] UNIV ASTON,INST PHARMACEUT SCI,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND
[2] BURTON DIST HOSP,PHARM MFG UNIT,BURTON TRENT,ENGLAND
关键词
D O I
10.1111/j.1365-2710.1994.tb00699.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of an oral formulation of 10 mg/ml caffeine citrate (equivalent to 5.03 mg/ml caffeine free base), which was preserved with potassium sorbate, was assessed at a range of temperatures. There was no appreciable change in pH or caffeine content over 1 year, even at storage temperatures of 32 degrees C and 45 degrees C. A batch-to-batch difference in the stability of potassium sorbate was detected, with losses over 1 year of 2% and 11% for two batches at 25 degrees C and 10% and 30%, respectively, at 45 degrees C. The formulation complied with the Antimicrobial Preservative Efficacy test of the British Pharmacopoeia throughout a period of storage at 25 degrees C for 1 year. There was no detectable benefit to preservative efficacy by adding 20% w/v sorbitol as an osmotic agent. The formula with no sorbitol may be preferable due to the potential for sorbitol to cause gastrointestinal upset. A shelflife of 1 year at room temperature is feasible. The additional precaution of limiting the in-use storage life to 1 month after opening is recommended to ensure acceptable microbiological quality.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 14 条
[11]   CONJUGATION REACTIONS IN NEWBORN INFANT - METABOLISM OF PARA-AMINOBENZOIC ACID [J].
VEST, MF ;
SALZBERG, R .
ARCHIVES OF DISEASE IN CHILDHOOD, 1965, 40 (209) :97-&
[12]  
1959, BRIT PHARM CODEX
[13]  
1986, HDB PHARM EXCIPIENTS
[14]  
1989, GUIDELINE SUBMITTING